CPHI to Hold Third Quarter 2016 Earnings Conference Call On Tuesday November 15, 2016 at 8:30 a.m. ET

Monday, November 7, 2016 General News J E 4

HAIKOU, China, Nov. 7, 2016 /PRNewswire/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE MKT: CPHI), an NYSE MKT listed corporation with its  fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it plans to hold its third quarter 2016 earnings conference call on Tuesday, November 15, 2016 at 8:30 a.m. ET.

Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 14850461. A replay of the call will be accessible through November 23, 2016 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 14850461.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit The Company routinely posts important information on its website.


Ms. Diana Na Huang CFAChina Pharma Holdings, Inc. Phone: +86-898-6681-1730 (China) Email:

To view the original version on PR Newswire, visit:

SOURCE China Pharma Holdings, Inc.



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
BONESUPPORT™ Announces Key Corporate Appointment T...
Yisheng Biopharma Announces Research Collaboration...